Literatur
- 1
Wehkamp J, Fellermann K, Herrlinger K R. et al .
Mechanisms of disease: defensins in gastrointestinal diseases.
Nat Clin Pract Gastroenterol Hepatol.
2005;
2
406-415
- 2
Wehkamp J, Harder J, Weichenthal M. et al .
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal
alpha-defensin expression.
Gut.
2004;
53
1658-1664
- 3
Wehkamp J, Salzman N H, Porter E. et al .
Reduced Paneth cell alpha-defensins in ileal Crohn’s disease.
Proc Natl Acad Sci USA.
2005;
102
18 129-18 134
- 4
Wehkamp J, Fellermann K, Herrlinger K R. et al .
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic
mucosa of inflammatory bowel disease.
Eur J Gastroenterol Hepatol.
2002;
14
745-752
Dr. med. Jan Wehkamp
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Auerbachstr. 112 · 70376 Stuttgart · Germany
Email: jan.wehkamp@ikp-stuttgart.de
